Update on Investigation, Interims and Auditors

AI SummaryClose X

SkinBioTherapeutics plc has completed its board investigation into financial statements, including those for the year ended 30 June 2025, and anticipates publishing its HY26 results alongside restated FY25 results and remediation plans shortly, after which trading in its ordinary shares is expected to resume. The company has appointed Saffrey LLP as its independent auditor for the financial year ending 30 June 2026, following a competitive tender process, and Gravita Audit II Limited has confirmed no circumstances require attention regarding its cessation of office.

Disclaimer*

UK 100

Latest directors dealings